



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 21ST OCTOBER 2020

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chairperson)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT (part of meeting)
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr G Sanna (GS)	Consultant Microbiologist, ELHT (part of meeting)
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr J Adiyodi (JA)	Consultant Haematologist, ELHT
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
Dr Y Nakhuda	Consultant Radiologist, ELHT
Mr J Bontoft	Independent Prescribing Optometrist, East Lancs (for item 2020/100 – 077)

2020/097: APOLOGIES:

Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr R Ahmed (RA)	GP BwD CCG
Dr T McKenzie (TM)	GP East Lancs

2020/098: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2020/099: MINUTES OF SEPTEMBER Teams MEETING:

Accepted as a correct record.

2020/100: MATTERS ARISING:

2019/131: Treatment of Vitamin B12 Deficiency Draft – A pathway is currently being developed with Jane Oakey from Path Lab who is exploring options re. active B12 testing in path lab. LR to obtain update on progress. To be brought to ELMMB when completed.

2020/015: New Product Request – Relvar Ellipta® & Anoro Ellipta® - JV arranging meeting to consider their place on primary care guidelines

2020/020: Formulary Updates - Ranolazine & Ivabradine – Dr Singh has prepared prescribing guidance. The guidance to be adopted and circulated as part of a Hot Topic to support GP prescribing. Cardiology pharmacist to ask cardiologists to refer GPs to guidance. Preparation and review dates to be added to documents and a link them to be included on formulary. Traffic light can now change to green. **Traffic Light: GREEN**

2020/077: Formulary Updates

- **CUES eye products** – James Bontoft, Independent Prescribing Optometrist, East Lancs, in attendance for this item to represent optometrists delivering the Covid Urgent Eye Service. The three items on their list of medications that are not on the ELHE formulary were discussed.
Ciprofloxacin eye drops are used by some optometrists. Ofloxacin is the quinolone of choice on formulary. Agreement reached that ofloxacin eye drops will remain on formulary and ciprofloxacin will not be added
Doxycycline 50mg tablet, used off licence, are an option to consider in NICE CKS for blepharitis. To be added to formulary for this indication, only under the direction of an optometrist **Traffic Light: AMBER**
Ketoralac eye drops may need to be continued post op for some patients. Remain amber on formulary but include optometrists as specialists to continue treatment.
- **GlucRx safety needles** – training information has gone to clinical teams.

2020/092: Drug Safety Update – Denosumab – ongoing.

2020/101: NEW PRODUCT REQUEST - DELAFLOXACIN

Requested by microbiology and presented by Dr Sanna, Consultant Microbiologist. Delafloxacin is a fourth generation quinolone with improved spectrum of activity, requested as second line for complex skin and soft tissue infections. It would be an option to facilitate earlier discharge for some patients as oral treatment has good absorption and is as effective as IV infusion. IV infusion would only be for patients for whom tablets are inappropriate. Anticipated use will be approximately 20 patients per year. Approved for use only on the recommendation of microbiologist.

Resolved: Delafloxacin included on formulary for use only on the advice of microbiologist. **Traffic Light: RED**

2020/102: LSCMMG CONSULTATIONS (FOR NOVEMBER LSCMMG)

Semaglutide oral tablets for Type 2 Diabetes New Medicines assessment – comments from ELMMB include:

- Evidence for HbA1c reduction and weight loss/reduction is not as good as with injectable formulations.
 - Has the potential to be more expensive
 - Use in combination with insulin has evidence, but when injecting with insulin could use an injectable GLP-1 receptor agonist which has more evidence
 - Not currently included in NICE which could pose a problem in the future if not approved by NICE
- ELMMB do not support the recommendation and suggest a black traffic light.

Dapagliflozin Shared Care Guideline – comments from ELMMB include:

- Renal function information needs to emphasise that it should not be started if eGFR is <60mL/min and be stopped if it falls to <45mL/min
- Review at 6 months by secondary care needs to be clearer.

Sativex for spasticity due to multiple sclerosis Shared Care Guideline – considered that prescribing of Sativex for this indication should remain with specialist service. Recommend change traffic light to red.

Resolved: Comments to be sent to LSCMMG.

2020/103: LSCMMG Recommendations

None added to website in September

2020/104: JOINT COMMITTEE OF CCGs COMMISSIONING DECISIONS

No meeting.

2020/105: FORMULARY UPDATES

Sucralfate oral suspension – add back to formulary as a licensed preparation is available again. No longer needs to be IMOT. **Traffic Light: AMBER**

Imipramine – change back from black to amber traffic light, for use in exceptional circumstances by Lancashire Care. **Traffic Light: AMBER**

Contour Next / Plus – the last review of blood glucose testing meters recommended Contour Plus along with Tee2 as the preferred meter of choice for new patients. Mass switching is not advised. Contour next is occasionally required for new patients that require Bluetooth to submit their results to the service.

The resources for blood glucose meters and strips to be consolidated and located together in the same location on the website. A table with the final version of meters and strips will be brought back to ELMMB before uploading.

Resolved: Formulary to be updated as above with final version brought back to next meeting.

2020/106: FENTANYL PATCHES IN PALLIATIVE CARE

Concern expressed from primary care that a couple of patients under the care of the palliative care team are changing their fentanyl patches after two days rather than every three days. These are individual patients with specific needs and there is some anecdotal evidence that this may be useful for some individuals. It is not a routine practice for palliative care. Individual patients should be discussed with GP.

Resolved: Individual patient needs for pain relief should be discussed with GP before advising prescribing outside of license.

2020/107: ADRENALINE AUTO INJECTOR POSITION STATEMENT & PATIENT INFORMATION LEAFLET

The position statement and patient information leaflet are intended to support prescribing of two adrenaline auto injectors only per patient. The patient should be advised to take them everywhere they go and not have multiple pens in different locations. Concern was expressed that this may not be practical in some situations and having extra pens for school should be an option. JV to discuss with LCC about what policies and procedures are in place for adrenaline auto injectors and if stocking auto injectors in schools is an option.

Action: JV will discuss with LCC and bring back to a future meeting of ELMMB.

2020/108: NON-CANCER PAIN GUIDELINE – OPIOID TAPERING & WITHDRAWAL

LR requested item is deferred to November to combine all related guidance.

2020/109: NICE RECOMMENDATIONS (from September)

Avelumab with axitinib for untreated advanced renal cell carcinoma [TA645] is recommended as an option by NICE. Approved in line with NICE.
Cancer Drugs Fund

Traffic Light: RED

Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) (TA646)

Traffic Light: BLACK

Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) (TA647)

Traffic Light: BLACK

Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)

Traffic Light: BLACK

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649).
NHS England Commissioned

Traffic Light: RED

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650) is not recommended by NICE.

Traffic Light: BLACK

Naldemedine for treating opioid-induced constipation (TA651) is recommended as an option by NICE. Approved in line with NICE.
CCG Commissioned **Traffic Light: Further information required before decision**

2020/110: EAMS:

Risdiplam is used to treat patients 2 months of age and older with type 1 or type 2 of a genetic disease called 'spinal muscular atrophy' (SMA) who are not suitable for authorised treatments.

Resolved: EAMS Risdiplam acknowledged

Additional Item: TRAZTUZUMAB – POST TRIAL ACCESS

For information – traztuzumab will be used via a free of charge post-trial access scheme for one patient.

Resolved: Acknowledged post-trial access traztuzumab.

STANDING ITEMS

2020/111: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES – September 2020

Minutes acknowledged

2020/112: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA NHS FT D&T MINUTES – September 2020

Minutes acknowledged

2020/113: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEES MINUTES – March 2020

Minutes acknowledged

2020/114: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEES MINUTES – July 2020

Minutes acknowledged

2020/115: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEES MINUTES – August 2020

Minutes acknowledged

2020/116: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEES MINUTES – September 2020

Minutes acknowledged

DATE OF NEXT MEETING – Wednesday 18th November 2020 12.30pm via 'Microsoft Teams'

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 21st OCTOBER 2020

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/131	Treatment Of Vitamin B12 Deficiency Draft – pathway to be developed.	LR/JV	Nov 20
2020/015	New Product request – Relvar Ellipta® & Anoro Ellipta® - meeting to be arranged to consider place on primary care guidelines	JV	Nov 20
2020/092	Drug Safety Update – Denosumab Invite representatives from rheumatology, MSK & medicine for older people to next meeting	CW/AG/LR	Oct 20
2020/105	Formulary Updates – Contour Plus /Next – table of blood glucose meters and strips to be updated. Resources on website to be consolidated in one location	LR / JV LR / JV	Nov 20 Nov 20
2020/107	Adrenaline Auto Injector Position Statement & Patient Information Leaflet – discuss policies & procedures in schools with LCC	JV	Dec 20